Definite diagnosis is based on endomyocardial biopsy and treatment of cardiac amyloidosis is a challenge. Heart transplantation, although controversial, has demonstrated survival benefit.
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
Patients with cardiac amyloidosis have very poor survival without ... Conventional heart failure drugs are usually not well tolerated and the long-term benefits are unclear. Cardiac ...
At our Cardiac Amyloidosis Clinic, people with a diagnosis of cardiac amyloidosis receive treatment from a team of experts. If you have related symptoms such as swelling of the ankles and legs ...
Hosted on MSN9mon
What Is Cardiac Amyloidosis?Your healthcare provider will likely prescribe you medications to treat your symptoms and help lower the risk of complications. There are two main types of cardiac amyloidosis: light chain ...
Diagnosis and treatment may be challenging at first because the symptoms and causes vary between different types of amyloidosis. They may also mimic other conditions, such as heart disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback